Intraoperative Radiotherapy for Early Breast Cancer

Masataka Sawaki

Department of Breast Oncology, Aichi Cancer Center Hospital, Japan

1. Introduction

The standard treatment for early breast cancer is breast-conserving therapy (BCT) with whole breast external irradiation therapy (WBI), and local control plays crucial role on survival (Clarke et al., 2005). It has been established that there is no significant difference in disease-free or overall survival rates between treatment by mastectomy or by lumpectomy with WBI for women with early breast cancer (Fisher et al., 2002; Veronesi et al., 2002). WBI actually provides statistically significant local control and survival data out to 15 years in favor of WBI compared to none (Clarke, et al., 2005). In actuality many women are still encouraged to proceed to mastectomy, because of the lack of access to radiotherapy centers or the long course of treatment of WBI. On the other hand, local recurrences after BCT with or without WBI arise most in the same quadrant as the primary cancer (Veronesi et al., 2001). The main objective of radiotherapy after BCT is considered to be the destruction of residual cancer cells in the operative field. Partial breast irradiation (PBI) has been tested in clinical trials for selected patients, and these studies have shown adequate local control, minimal toxicity, and good cosmetic appearance (Njeh et al., 2010). Intraoperative radiotherapy (IORT) is one of these PBI methods, which has recently been used in early stage breast cancer. Partial breast radiation therapy administered around the tumor bed has been comparable to WBI in selected patients (Antonucci et al., 2009; Benitez et al., 2007; Vicini et al., 2001; Vicini et al., 2003). Many phase II or III trials evaluating adjuvant IORT are actively accruing patients in the United States (NSABP-B39), Europe, United Kingdom, and Australia (Holmes et al., 2007). The standard treatment for early breast cancer is BCT with WBI, and outside the setting of a clinical trial, use of IORT as well as accelerated partial breast irradiation (APBI) is not yet recommended (Njeh, et al., 2010; Skandarajah et al., 2009). Then, particularly in practice setting, patients’ selection is critical to the successful application of PBI (Polgár et al., 2010; Vicini et al., 2011).

This review concentrates on the eligibility, methods, outcome, and the point at issue of IORT for early breast cancer. With regard to terms, I defined IORT as the delivery of single fractional dose irradiation directly to the tumor bed during operation, and PBI as irradiation confined to the tumor bed either during operation or after surgery.
2. Eligibility for IORT – Who is suitable for IORT?

Many attempts have been made to identify subgroups of patients who might avoid radiotherapy after BCT, but these are not distinct factors. In general, the risk factors for local recurrence after BCT are larger tumor size, higher tumor grade, younger age, lymph node-positive, and close surgical margin (Clarke, et al., 2005; Fisher, 1997; Park et al., 2000). Then, we review clinical questions of which patients can be considered for IORT. Some points are discussed separately as below.

2.1 Age

Cumulative incidence of recurrence of tumor in the ipsilateral breast after WBI with a boost is different among age, younger women have higher incidence (Bartelink et al., 2007). Age ≥ 50 years has been selected in most prospective trials, and studies have shown that elderly patients treated with WBI (Antonini et al., 2007; Bartelink, et al., 2007) or MammoSite® (Chao et al., 2007) were low risk. Few women younger than 50 has been treated with PBI in prospective single arm studies.

2.2 Tumor size

A maximum tumor size of 2cm has been selected in most prospective trials. T2 tumors (>2cm, ≤5cm) or T0 (ductal carcinoma in situ; DCIS) tumors are cautionary recommended (Smith et al., 2009). Patients with T3 or T4 tumors should not receive PBI. An extensive intraductal component should be treated with caution. Patients with multicentric tumors; i.e. presence of foci of cancer in different quadrants, should not receive PBI because of the extent of disease. Patients of clinically unifocal or multifocal tumors with a total tumor size no greater than 2 cm could be suitable for PBI (Smith, et al., 2009).

2.3 Nodal status

Node positive is one of the risk factor for ipsilateral breast cancer (Clarke, et al., 2005). Then, majority of patients who have been treated in prospective single arm APBI trials had pathologically node negative disease. Patients who do not undergo surgical nodal assessment or who have pathologic evidence of nodal involvements should not receive PBI.

2.4 Pathology

One area of concern in the use of IORT is the management of positive surgical margins as positivity is discovered at the final histology, a few days after surgery and IORT. Attention should be paid to ensure negative margins on final pathology (Beal et al., 2007), although margin positivity does not always influence the rate of local recurrences if effective radiotherapy is delivered (Chism et al., 2006; Mariani et al., 1998; Veronesi et al., 2010). Intraoperative frozen sections may be used to reduce positive margins (Fukamachi et al., 2010). Patients with close but negative margins (<2 mm) may be treated with caution (Smith, et al., 2009). Tumors with higher tumor grade is not suitable for PBI, because it is one of risk factors for local recurrence and most prospective trials have not considered as eligibility criteria. As for the tumor characteristics biologically, such as HER2-type or basal-type have
been shown to involve higher risk for local recurrence than luminal A or B-types (Kyndi et al., 2008; Nguyen et al., 2008; Veronesi, et al., 2010), then tailored local-regional treatment for early-stage breast cancer has been reported to be mandatory now (Solin, 2010).

2.5 Oncology

There has been only limited study of IORT including PBI in patients receiving neoadjuvant or concurrent chemotherapy. For patients who will receive adjuvant chemotherapy, it is recommended that APBI be performed first and that there should be an interval of at least 2 to 3 weeks between completion of APBI and initiation of chemotherapy (Smith, et al., 2009). Thus, IORT including PBI allows radiotherapy to be given without delaying administration of chemotherapy or hormonal therapy. But careful observation is needed; a retrospective analysis from MammoSite registry single arm trial reported an association between initiation of adjuvant chemotherapy within 3 weeks of the last MammoSite treatment and an increased risk of both radiation recall skin retraction and suboptimal cosmetics (Haffty et al., 2008). There is no data when adjuvant endocrine therapy with APBI should be started.

We show recommendation for APBI in Table 1.

<table>
<thead>
<tr>
<th>Factors</th>
<th>Suitable group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>≥60</td>
</tr>
<tr>
<td>BRCA1/2 mutation</td>
<td>Not present</td>
</tr>
<tr>
<td>Tumor size</td>
<td>≤2 cm</td>
</tr>
<tr>
<td>T stage</td>
<td>T1</td>
</tr>
<tr>
<td>Margins</td>
<td>Negative by at least 2 mm</td>
</tr>
<tr>
<td>Grade</td>
<td>Any</td>
</tr>
<tr>
<td>LVSI</td>
<td>No</td>
</tr>
<tr>
<td>ER status</td>
<td>Positive</td>
</tr>
<tr>
<td>Multicentricity</td>
<td>Unicentric only</td>
</tr>
<tr>
<td>Mutifocally</td>
<td>Clinically unifocal with total size ≤2 cm</td>
</tr>
<tr>
<td>Histology</td>
<td>Invasive ductal or other favorable subtypes</td>
</tr>
<tr>
<td>Pure DCIS</td>
<td>Not allowed</td>
</tr>
<tr>
<td>EIC</td>
<td>Not allowed</td>
</tr>
<tr>
<td>Associated LCIS</td>
<td>Allowed</td>
</tr>
<tr>
<td>Nodal status</td>
<td>pN0</td>
</tr>
<tr>
<td>Nodal surgery</td>
<td>SN Bx or ALND</td>
</tr>
<tr>
<td>Neoadjuvant Therapy</td>
<td>Not allowed</td>
</tr>
</tbody>
</table>

Table 1. Suitable patient group recommendation selections for APBI outside of clinical trials; ASTRO Consensus Statement (Smith, et al., 2009)

3. Radiation methods

Several radiation methods are commonly in use for IORT. We show various radiation techniques for IORT in Table 2.
<table>
<thead>
<tr>
<th>Author</th>
<th>Year (publish)</th>
<th>No. of cases</th>
<th>Median follow up (months)</th>
<th>Technique</th>
<th>Ipsilateral breast cancer recurrence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sawaki M</td>
<td>2011</td>
<td>32</td>
<td>26</td>
<td>Electrons</td>
<td>0</td>
</tr>
<tr>
<td>Veronesi U</td>
<td>2010</td>
<td>1,822</td>
<td>36.1</td>
<td>Electrons</td>
<td>1.3</td>
</tr>
<tr>
<td>Vaidya JS</td>
<td>2010</td>
<td>854</td>
<td>48</td>
<td>Photons</td>
<td>1.2</td>
</tr>
<tr>
<td>Lemanski C</td>
<td>2010</td>
<td>42</td>
<td>30</td>
<td>Electrons</td>
<td>4.8</td>
</tr>
<tr>
<td>Mussari S</td>
<td>2006</td>
<td>47</td>
<td>48</td>
<td>Electrons</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2. Clinical studies using full-dose Intraoperative radiation therapy (IORT)

3.1 Electrons Intraoperative Therapy (ELIOT)

3.1.1 As a single fractional dose

ELIOT is one of these PBI methods, which has recently been used in early stage breast cancer, mainly at the European Institute of Oncology (Italian: *Istituto Europeo di Oncologia*; IEO) in Milan since 1999 (Intra et al., 2006; Luini et al., 2005; Veronesi et al., 2005; Veronesi et al., 2010; Veronesi et al., 2001). They have been promoted to prospective trials to investigate tolerance to increased IORT doses and ultimately to introduce the use of 21 Gy in the context of breast conserving surgery. A single dose of 21 Gy at 90% isodose has been shown to be feasible in European breast cancer patients and biologically equivalent to a full dose of conventional WBI (Intra et al., 2006; Luini et al., 2005; Veronesi et al., 2005; Veronesi et al., 2001). The main advantages are follows. 1) To be able to deliver the radiation before tumor cells have a chance to proliferate under surgical intervention have a rich vascularization, which makes them more sensitive to the action of the radiation. 2) To be able to deliver under direct visualization at the time of surgery. It has the potential for accurate dose delivery by permitting delivery of the radiation dose directly to the surgical margins. 3) IORT could minimize some potential side effects, since skin and the subcutaneous tissue can be displaced. 4) The spread of irradiation to lung and heart is reduced significantly. 5) IORT allows radiotherapy to be given without delaying administration of chemotherapy or hormonal therapy. 6) There is potential for decreasing healthcare cost, because it is one fraction as opposed to 25 fractions. For elderly patients, it is feasible and corresponded to acceptable quality index criteria (Lemanski et al., 2010). In Asian breast cancer patients 21 Gy was recommended as a result of phase I study, which had been used a scheme of dose-escalation from 19, 20, and 21 Gy. (Sawaki et al., 2009), and subsequent phase II study indicated feasibility at 21 Gy (Sawaki et al., 2011). In this technique a disk should be needed to reduce the spread of irradiation to lung and heart. The disk is located between gland and pectoralis muscle. The aluminum and lead disk has been used in Italy (Intra et al., 2006; Mussari et al., 2006). As for an another kind of disk, two layers disk; a first layer (source side) of polymethyl methacrylate (PMMA) and a second layer of copper was designed and selected from metals such as aluminum, copper and lead after testing for their shielding capabilities and the range of the backscatter (Oshima et al., 2009).

IORT extends the primary operation only for an additional 15 minutes plus approximately 30 minutes of a radiotherapy physicist’s time to prepare the device (Sawaki et al., 2009), although conventional WBI radiotherapy usually requires 5 weeks of outpatient treatment.

www.intechopen.com
The largest randomized clinical trial to date is now in progress at the Milan Institute. The goal of the trial is to determine the equivalence of local recurrence rates between quadrantectomy with conventional WBI and that with IORT. To date, they remain investigational until information on its long-term efficacy and safety becomes available (Buchholz, 2009). In the trial at the Milan Institute, 21 Gy, which is recommended through more than 1000 IORT procedures (Intra, et al., 2006), was used for the IORT arm. In the most update data, local recurrence rate was 1.3% (24/1,822) (Veronesi, et al., 2010). In addition, IORT can achieve early initiation of radiotherapy (RT). Delay in the initiation of RT is associated with a decrease in local recurrence rate (Huang, 2003).

3.1.2 As a boost

With regard to another concept of full-dose intraoperative radiotherapy, an anticipated boost during operation has been studied (Reitsamer et al., 2002; Reitsamer et al., 2006). A single dose of 9 Gy was applied to the 90% reference isodose with energies ranging from 4 to 15 MeV, using round applicator tubes 4–8 cm in diameter. After wound healing, the patients received additional 51 – 56 Gy external boost radiation (EBRT) to the whole breast (Reitsamer, et al., 2002). The advantages are follows. 1) To complete skin sparing, 2) the precise application of the boost directly to the tumor bed with a homogeneous tissue radiation and 3) to reduce postoperative radiation time for 7-10 days (time of postoperative boost radiotherapy) (Reitsamer, et al., 2002; Reitsamer, et al., 2006).

3.1.3 Nipple sparing mastectomy

Nipple sparing mastectomy can be applied for treatment of breast cancer when mastectomy is indicated. To reduce the risk of retro areolar recurrence, radio-surgical treatment combining subcutaneous mastectomy with intraoperative radiotherapy (ELIOT) is proposed (Petit et al., 2009; Petit et al., 2009). The IORT with electrons of 16 Gy in one shot was delivered on the nipple areolar area. Local recurrence rate was not higher than the usual rate observed in the literature, although longer follow up is needed.
3.2 Targeted intraoperative radiotherapy (TARGIT)

This device is inserted intraoperatively into the tumor cavity after excision of the tumor and emits X-rays from within the breast (Vaidya et al., 2010). The authors used a miniature electron-beam-driven X-ray source called Intrabeam®, which emits low energetic X-rays with 50 kV from the point source. In large randomized clinical trial, TARGIT trial for selected patients with early breast cancer, a single dose of radiotherapy delivered at the time of surgery by use of targeted intraoperative radiotherapy is considered as an alternative to external beam radiotherapy delivered over several weeks (Vaidya, et al., 2010), although it needs longer follow up to conclude the no inferiority to the WBI (Reitsamer et al., 2010).

4. Conclusion

In conclusion, IORT is an option applied for breast conserving therapy in the selected patients. TARGIT trial has been considered as an alternative to external beam radiotherapy delivered over several weeks (Vaidya, et al., 2010). And also ELIOT appears a promising feature in early breast cancer treated with breast conserving surgery, reducing the exposure of normal tissues to radiations and shortening the radiation course from 6 weeks to one single session (Veronesi, et al., 2010). These clinical studies have shown adequate local control, minimal toxicity, and good cosmetic appearance, although a longer follow up is needed for the evaluation of the late side effects. In practice setting, careful management is needed because patients’ selection is critical to the successful application of IORT.
5. Conflict of Interest

The author states that I have no conflict of interest.

6. Acronyms and abbreviations

ALND; Axillary lymph node dissection
APBI; Accelerated partial breast irradiation
ASTRO; American Society for Radiation Oncology
BCT; Breast conserving therapy
DCIS; Ductal carcinoma in situ
EBRT; External boost radiation
EIC; Extensive intraductal component
ELIOT; Electrons intraoperative therapy
ER; Estrogen receptor
IORT; Intraoperative radiotherapy
LCIS; lobular carcinoma in situ
LVSI; Lymph-vascular space invasion
PBI; Partial breast irradiation
PMMA; polymethyl methacrylate
RT; Radiotherapy
SN Bx; Sentinel lymph node biopsy
TARGET; Targeted intraoperative radiotherapy
WBI; Whole breast external irradiation therapy

7. References


Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. It is an enormous global health encumbrance, growing at an alarming pace. Global statistics show that in 2030 alone, about 21.4 million new cancer cases and 13.2 million cancer deaths are expected to occur, simply due to the growth, aging of the population, adoption of new lifestyles and behaviors. Amongst the several modes of treatment for cancer available, Radiation treatment has a major impact due to technological advancement in recent times. This book discusses the pros and cons of this treatment modality. This book “Modern Practices in Radiation Therapy” has collaged topics contributed by top notch professionals and researchers all around the world.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
